Myriad Genetics price target raised to $44 from $42 at Cantor Cantor increased its price target on Myriad Genetics after CMS raised prices for the company's BRCA 1&2 tests by about 52%, according to the firm. Cantor raised its estimates for Myriad Genetics and keeps a Buy rating on the stock.
Myriad Genetics, Tufts Health Plan sign agreement to cover Prolaris Myriad Genetics announced that it has signed a three-year contract with Tufts Health Plan through which the plan will provide coverage of Prolaris for members diagnosed with localized prostate cancer. Prolaris is the first and only biopsy test validated against prostate cancer specific mortality. Tufts Health Plan is a leading health plan in the Northeast with more than one million members. Tufts Health Plan's members will benefit from this agreement, which is designed to drive optimal treatment because men can confidently pursue active surveillance for tumors identified as being less aggressive with Myriad's extensively validated Prolaris combined score. Recent data show that many men realize no benefit from interventional treatment, and many suffer needlessly from the side effects associated with radical prostatectomy and radiation.